OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

NCT04493632 | Recruiting DMC

• 1 other identifier: OSPREY01
• Study Type: observational
• Target: 500
• Locations: 2 countries
• Sites: 9

Brief Summary

The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry. The Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.

Conditions

Pancreatic Neoplasm; Digestive System Neoplasm; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasm; Digestive System Disease; Pancreatic Diseases; Endocrine System Diseases

Keywords

Pancreatic Cancer; Pancreas; Metastases; Pancreatic tumor; Unresectable; Locally advanced; Implantable; Radiographic; Device; Phosphorous-32; OncoSil™; Brachytherapy; Gemcitabine; Nab-paclitaxel; Abraxane

Outcome Measures

Primary Outcomes (5)

• Safety and tolerability of Device

  The analysis for safety within the real-world setting will be performed. The safety of OncoSil™ is defined by the Adverse Event profile. All safety summaries will be produced for the Intention-To-Treat (ITT) population. Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA). All Adverse Events recorded during the Registry will be listed. Summary tables will be produced for Treatment Emergent Adverse Events (TEAEs). The number and percentage of patients with device-related Adverse Events by system organ class (SOC) and preferred term will be tabulated. Similar summaries will be produced by severity of event (both mild, moderate or severe, CTCAE grade 1-4) and drug and/or device relationship. In addition, summary tables will be produced for serious TEAEs and TEAEs associated with special interest acute/late radiation effects and or withdrawal.

  Followed to death or to 24-months post the date of the last enrolled patient implanted with OncoSil™

• Device Implantation Performance

  Safety of the implantation of OncoSil™ within the target tumour will be measured by means of procedure-related Adverse Events. An assessment of the utility of OncoSil™ Implantation will be made and listed appropriately.

  7 years

• Overall Survival

  Overall survival (OS) is defined as the time from enrolment to the date of death from any cause. Patients who are alive or permanently lost to follow-up at the cut-off date for the analysis will be censored at the last date the patient was known to be alive. Overall Survival (OS) will be analysed at the interim analysis and once all 500 OncoSil™ implanted patients have been followed to death or to 24-months post the date of the last enrolled/treated patient.

  Followed to death or to 24-months post the date of the last enrolled patient implanted with OncoSil™

• tumour response as demonstrated by target tumour response demonstrated by RECIST 1.1

  Target (implanted) tumor response (local and distant)

  7 years

• Resection Rates

  Surgical resection rates and outcome

  7 years

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Every patient who is intended to undergo implantation of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, in the commercial (sales) setting will be approached by the Treating Physician to consent to participate in the OSPREY Patient Registry. Patients who choose not to consent to participate in the OSPREY Patient Registry will not be excluded from being treated with the OncoSil™ device. .

You may qualify if:

• Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).
• Patients who undergo OncoSil™ implantation at an eligible treatment facility.
• Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry.
• Pancreatic target tumour recommended size of \<7 cm (longest diameter) and \<110 cc volume.
• A clinically acceptable ECOG performance status.
• Patients ≥ 18 years of age at screening.
• To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment.
• Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician.

You may not qualify if:

• Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry.
• Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).
• Evidence of distant metastases based on review of baseline CT scan.
• More than one primary lesion.
• In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes:
• where previous EUS-FNA was considered technically too difficult to perform;
• imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;
• presence (or significant risk) of varices near to the target tumour.
• Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).
• In the setting of recent, clinically significant pancreatitis, implantation is not recommended.
• Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding.
• Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components

Sponsors & Collaborators

• OncoSil Medical Limited: lead

Study Sites (9)

Complejo Hospitalario Universitario Insular Materno-Infantil

Las Palmas de Gran Canaria, Spain

RECRUITING

Hospital Universitario Ramón y Cajal

Madrid, 28034, Spain

RECRUITING

Hospital Universitario de Fuenlabrada

Madrid, 28942, Spain

RECRUITING

Hospital Universitario Doce De Octobre

Madrid, Spain

NOT YET RECRUITING

Hospital Universitario La Paz

Madrid, Spain

NOT YET RECRUITING

Clinica Universidad De Navarra

Pamplona, Spain

RECRUITING

Hospital Clinico Universitario De Valladolid

Valladolid, Spain

RECRUITING

Hammersmith Hospital

London, United Kingdom

NOT YET RECRUITING

The London Clinic

London, United Kingdom

NOT YET RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Paul J Ross, MRCP, MBBS

  Guy's and St Thomas' NHS Foundation Trust, London, UK

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tom Maher

CONTACT

+44 750 4658585; tom.maher@oncosil.com

Nicole G Gaddi, B.Sc Nursing

CONTACT

+ 61 (0)428 946 588; nicole.gaddi@oncosil.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 24 Months
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2020
• First Posted: July 30, 2020
• Study Start: April 12, 2022
• Primary Completion: November 1, 2025
• Study Completion (Estimated): October 1, 2027
• Last Updated: April 30, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

ES (7); GB (2)